Supplementary Material

Leukotriene-receptor antagonist and risk of neuropsychiatric events in children, adolescents, and young adults: A self-controlled case series

Ji Soo Park, Yoo Jung Cho, Je-Yeon Yun, Hye Jin Lee, Jinho Yu, Hyeon-Jong Yang, Dong In Suh, on behalf of the Korean childhood Asthma REsearch team

Contents

Supplementary Text	2
Supplementary Table S1	
Supplementary Table S2	
Supplementary Table S3	
Supplementary Table S4	
Supplementary Table S5	
Supplementary Table S6	
Supplementary Table S7	
Supplementary Table S9	
Supplementary Figure S1	
Reference	

Supplementary Text

MATERIALS AND METHODS

Assessment of exposure

One of the main assumptions that the SCCS method relies on is that events do not influence subsequent exposures. To test for this assumption, we drew a histogram of the time interval between the first event of each patient (t) and the starting date of exposures (u) before and after the first event was plotted. [1] In this case, the first event (t) is the first NPE of each participant, and the starting date of exposures (u) is the date of LTRA prescription. The x-axis is the number of days from start of LTRA prescription to an NPE (t-u). The events on the negative x-axis are events that occurred before the start of exposure, meaning the LTRA was prescribed after the NPE. The events on the positive x-axis are events that occurred after the start of exposure, meaning the LTRA was prescribed before the NPE. If events were sparse in the negative intervals compared to the positive intervals, this would indicate that exposures were delayed after an event (i.e., the event influenced the exposure). If LTRAs were less frequently prescribed due to an NPE, than the events on the negative x-axis is expected, as these are the events of interest to our study hypothesis. The NPEs that are expected shortly after prescription of LTRA would form a peak on the short positive x-axis.

Supplementary Table S1. International Statistical Classification of Diseases and Related Health Problems, 10th edition (ICD-10) codes for neuropsychiatric diagnoses

Type of	ICD-	
neuropsychiatric	10	Diagnosis
diagnosis	code	
Psychotic		
disorder		
	F20	Schizophrenia
	F20.0	Paranoid schizophrenia
	F20.1	Hebephrenic schizophrenia
	F20.2	Catatonic schizophrenia
	F20.3	Undifferentiated schizophrenia
	F20.4	Post-schizophrenic depression
	F20.5	Residual schizophrenia
	F20.6	Simple schizophrenia
	F20.8	Other schizophrenia
	F20.9	Schizophrenia, unspecified
	F21	Schizotypal disorder
	F22	Persistent delusional disorders
	F22.0	Delusional disorder
	F22.8	Other persistent delusional disorders
	F22.9	Persistent delusional disorder, unspecified
	F23	Acute and transient psychotic disorders

F23.0	Acute polymorphic psychotic disorder without symptoms of
	schizophrenia
F23.1	Acute polymorphic psychotic disorder with symptoms of
	schizophrenia
F23.2	Acute schizophrenia-like psychotic disorder
F23.3	Other acute predominantly delusional psychotic disorders
F23.8	Other acute and transient psychotic disorders
F23.9	Acute and transient psychotic disorder, unspecified
F24	Induced delusional disorder
F25	Schizoaffective disorders
F25.0	Schizoaffective disorder, manic type
F25.1	Schizoaffective disorder, depressive type
F25.2	Schizoaffective disorder, mixed type
F25.8	Other schizoaffective disorders
F25.9	Schizoaffective disorder, unspecified
F28	Other nonorganic psychotic disorders
F29	Unspecified nonorganic psychosis
R41.0	Disorientation, unspecified
R44	Other symptoms and signs involving general sensations and
	perceptions
R44.0	Auditory hallucinations
R44.1	Visual hallucinations

- R44.2 Other hallucinations
- R44.3 Hallucinations, unspecified

Other and unspecified symptoms and signs involving general

R44.8

sensations and perceptions

Mood disorder

F30	Manic episode
F30.0	Hypomania
F30.1	Mania without psychotic symptoms
F30.2	Mania with psychotic symptoms
F30.8	Other manic episodes
F30.9	Manic episode, unspecified
F31	Bipolar affective disorder
F31.0	Bipolar affective disorder, current episode hypomanic
F31.1	Bipolar affective disorder, current episode manic without
ГЭІ.І	psychotic symptoms
F31.2	Bipolar affective disorder, current episode manic with
1'31.2	psychotic symptoms
F31.3	Bipolar affective disorder, current episode mild or moderate
131.3	depression
F31.4	Bipolar affective disorder, current episode severe depression
1'31.4	without psychotic symptoms
F31.5	Bipolar affective disorder, current episode severe depression
гэ1.Э	with psychotic symptoms
F31.6	Bipolar affective disorder, current episode mixed
F31.7	Bipolar affective disorder, currently in remission
F31.8	Other bipolar affective disorders

F31.9	Bipolar	affective	disorder,	unspecified

- F32 Depressive episode
- F32.0 Mild depressive episode
- F32.1 Moderate depressive episode
- F32.2 Severe depressive episode without psychotic symptoms
- F32.3 Severe depressive episode with psychotic symptoms
- F32.8 Other depressive episodes
- F32.9 Depressive episode, unspecified
- F33 Recurrent depressive disorder
- F33.0 Recurrent depressive disorder, current episode mild
- F33.1 Recurrent depressive disorder, current episode moderateRecurrent depressive disorder, current episode severe withoutF33.2
 - psychotic symptoms

Recurrent depressive disorder, current episode severe with

psychotic symptoms

- F33.4 Recurrent depressive disorder, currently in remission
- F33.8 Other recurrent depressive disorders
- F33.9 Recurrent depressive disorder, unspecified
- F34 Persistent mood [affective] disorders
- F34.0 Cyclothymia
- F34.1 Dysthymia

F33.3

- F34.8 Other persistent mood [affective] disorders
- F34.9 Persistent mood [affective] disorder, unspecified
- F38 Other mood [affective] disorders

F38.0	Other single mood [affective] disorders
F38.1	Other recurrent mood [affective] disorders
F38.8	Other specified mood [affective] disorders
F39	Unspecified mood [affective] disorder

Anxiety

F40	Phobic anxiety disorders
F40.0	Agoraphobia
F40.1	Social phobias
F40.2	Specific (isolated) phobias
F40.8	Other phobic anxiety disorders
F40.9	Phobic anxiety disorder, unspecified
F41	Other anxiety disorders
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F41.2	Mixed anxiety and depressive disorder
F41.3	Other mixed anxiety disorders
F41.8	Other specified anxiety disorders
F41.9	Anxiety disorder, unspecified
F42	Obsessive-compulsive disorder
F42.0	Predominantly obsessional thoughts or ruminations
F42.1	Predominantly compulsive acts [obsessional rituals]
F42.2	Mixed obsessional thoughts and acts
F42.8	Other obsessive-compulsive disorders

F42.9	Obsessive-compulsive disorder, unspecified
F43	Reaction to severe stress, and adjustment disorders
F43.0	Acute stress reaction
F43.1	Post-traumatic stress disorder
F43.2	Adjustment disorders
F43.8	Other reactions to severe stress
F43.9	Reaction to severe stress, unspecified
F44	Dissociative [conversion] disorders
F44.0	Dissociative amnesia
F44.1	Dissociative fugue
F44.2	Dissociative stupor
F44.3	Trance and possession disorders

- F44.4 Dissociative motor disorders
- F44.5 Dissociative convulsions
- F44.6 Dissociative anaesthesia and sensory loss
- F44.7 Mixed dissociative [conversion] disorders
- F44.8 Other dissociative [conversion] disorders
- F44.9 Dissociative [conversion] disorder, unspecified
- F45 Somatoform disorders
- F45.0 Somatization disorder
- F45.1 Undifferentiated somatoform disorder
- F45.2 Hypochondriacal disorder
- F45.3 Somatoform autonomic dysfunction
- F45.4 Persistent somatoform pain disorder

F45.8	Other somatoform disorders
F45.9	Somatoform disorder, unspecified
F48	Other neurotic disorders
F48.0	Neurasthenia
F48.1	Depersonalization-derealization syndrome
F48.8	Other specified neurotic disorders
F48.9	Neurotic disorder, unspecified
R45.1	Restlessness and agitation

Sleep-related

F51	Nonorganic sleep disorders
F51.0	Nonorganic insomnia
F51.1	Nonorganic hypersomnia
F51.2	Nonorganic disorder of the sleep-wake schedule
F51.3	Sleepwalking [somnambulism]
F51.4	Sleep terrors [night terrors]
F51.5	Nightmares
F51.8	Other nonorganic sleep disorders
F51.9	Nonorganic sleep disorder, unspecified
G47	Sleep disorders
G47.0	Disorders of initiating and maintaining sleep [insomnias]
G47.1	Disorders of excessive somnolence [hypersomnias]
G47.2	Disorders of the sleep-wake schedule
G47.3	Sleep apnoea

G47.30	Obstructive sleep apnoea
G47.31	Central sleep apnoea
G47.32	Mixed sleep apnoea
G47.38	Other sleep apnoea
G47.4	Narcolepsy and cataplexy
G47.8	Other sleep disorders
G47.9	Sleep disorder, unspecified

Cognitive

R41.1	Anterograde amnesia
R41.2	Retrograde amnesia
R41.3	Other amnesia
F90	Hyperkinetic disorders
F90.0	Disturbance of activity and attention
F90.1	Hyperkinetic conduct disorder
F90.8	Other hyperkinetic disorders
F90.9	Hyperkinetic disorder, unspecified
	Other behavioural and emotional disorders with onset usually
F98	occurring in
	childhood and adolescence
F98.0	Nonorganic enuresis
F98.1	Nonorganic encopresis
F98.2	Feeding disorder of infancy and childhood
F98.3	Pica of infancy and childhood

F98.4	Stereotyped movement disorders
F98.5	Stuttering[stammering]
F98.6	Cluttering
	Other specified behavioural and emotional disorders with
F98.8	onset usually occurring in
	childhood and adolescence
	Unspecified behavioural and emotional disorders with onset
F98.9	usually occurring in
	childhood and adolescence

Movement

G20	Parkinson's disease
G21	Secondary parkinsonism
G21.0	Malignant neuroleptic syndrome
G21.1	Other drug-induced secondary parkinsonism
G21.2	Secondary parkinsonism due to other external agents
G21.3	Postencephalitic parkinsonism
G21.4	Vascular parkinsonism
G21.8	Other secondary parkinsonism
G21.9	Secondary parkinsonism, unspecified
G24	Dystonia
G24.0	Drug-induced dystonia
G24.1	Idiopathic familial dystonia
G24.2	Idiopathic nonfamilial dystonia

	G24.3	Spasmodic torticollis
	G24.4	Idiopathic orofacial dystonia
	G24.5	Blepharospasm
	G24.8	Other dystonia
	G24.9	Dystonia, unspecified
	G25	Other extrapyramidal and movement disorders
	G25.0	Essential tremor
	G25.1	Drug-induced tremor
	G25.2	Other specified forms of tremor
	G25.3	Myoclonus
	G25.4	Drug-induced chorea
	G25.5	Other chorea
	G25.6	Drug-induced tics and other tics of organic origin
	G25.8	Other specified extrapyramidal and movement disorders
	G25.9	Extrapyramidal and movement disorder, unspecified
Personality		

F60	Specific personality disorders
F60.0	Paranoid personality disorder
F60.1	Schizoid personality disorder
F60.2	Dissocial personality disorder
F60.3	Emotionally unstable personality disorder
F60.4	Histrionic personality disorder
F60.5	Anankastic personality disorder

- F60.7 Dependent personality disorder
- F60.8 Other specific personality disorders
- F60.9 Personality disorder, unspecified
- F61 Mixed and other personality disorders
- F62 Enduring personality changes, not attributable to brain damage and disease
- F62.0 Enduring personality change after catastrophic experience
- F62.1 Enduring personality change after psychiatric illness
- F62.8 Other enduring personality changes
- F62.9 Enduring personality change, unspecified
- F63 Habit and impulse disorders
- F63.0 Pathological gambling
- F63.1 Pathological fire-setting[pyromania]
- F63.2 Pathological stealing[kleptomania]
- F63.3 Trichotillomania
- F63.8 Other habit and impulse disorders
- F63.9 Habit and impulse disorder, unspecified
- F64 Gender identity disorders
- F64.0 Transsexualism
- F64.1 Dual-role transvestism
- F64.2 Gender identity disorder of childhood
- F64.8 Other gender identity disorders
- F64.9 Gender identity disorder, unspecified

F65	Disorders of sexual preference
F65.0	Fetishism
F65.1	Fetishistic transvestism
F65.2	Exhibitionism
F65.3	Voyeurism
F65.4	Paedophilia
F65.5	Sadomasochism
F65.6	Multiple disorders of sexual preference
F65.8	Other disorders of sexual preference
F65.9	Disorder of sexual preference, unspecified
Ecc	Psychological and behavioural disorders associated with
F66	sexual development and orientation
F66.0	Sexual maturation disorder
F66.1	Egodystonic sexual orientation

- F66.2 Sexual relationship disorder
- F66.8 Other psychosexual development disorders
- F66.9 Psychosexual development disorder, unspecified
- F68 Other disorders of adult personality and behaviour
- F68.0 Elaboration of physical symptoms for psychological reasons
- Intentional production or feigning of symptoms or disabilities, F68.1
- either physical or psychological [factitious disorder]
- F68.8 Other specified disorders of adult personality and behaviour
- F69 Unspecified disorder of adult personality and behaviour

 F94 F94.0 Elective mutism F94.1 Reactive attachment disorder of childhood F94.2 Disinhibited attachment disorder of childhood F94.8 Other childhood disorders of social functioning F94.9 Childhood disorder of social functioning, unspecified 	F94	Disorders of social functioning with onset specific to
F94.1 Reactive attachment disorder of childhoodF94.2 Disinhibited attachment disorder of childhoodF94.8 Other childhood disorders of social functioning	1774	childhood and adolescence
F94.2 Disinhibited attachment disorder of childhoodF94.8 Other childhood disorders of social functioning	F94.0	Elective mutism
F94.8 Other childhood disorders of social functioning	F94.1	Reactive attachment disorder of childhood
	F94.2	Disinhibited attachment disorder of childhood
F94.9 Childhood disorder of social functioning, unspecified	F94.8	Other childhood disorders of social functioning
	F94.9	Childhood disorder of social functioning, unspecified

Supplementary Table S2. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or

		Childı	ren (3–11 years)			Adolesco	Young adult (19–30 years)							
Variable	No of events	Person- year	IRR (95% CI)	P-value	No of events	Person- year	IRR (95% CI)	P-value	No of events	Person- year	IRR (95% CI)	P-value		
Observation	period 1													
Unexposed	1,193	3062.25	1		684	1707.66	1		3,417	7749.78	1			
Exposed	48	154.55	0.72 (0.53, 0.97)	0.036	19	46.14	1.10 (0.65, 1.75)	0.707	63	170.80	0.94 (0.72, 1.22)	0.675		
Time since in	itiation of	LTRA (dag	ys)											
1-3	7	43.67	0.38 (0.16, 0.74)	0.011	5	12.57	1.03 (0.37, 2.24)	0.950	16	51.62	0.79 (0.46, 1.26)	0.359		
4-7	14	24.28	1.36 (0.76, 2.23)	0.255	4	7.16	1.44 (0.44, 3.42)	0.469	13	26.48	1.25 (0.69, 2.08)	0.421		
8-14	7	27.95	0.59 (0.25, 1.16)	0.170	3	7.47	1.05 (0.26, 2.78)	0.939	17	26.25	1.64 (0.97, 2.58)	0.047		
15-30	9	30.05	0.69 (0.33, 1.26)	0.275	4	8.38	1.25 (0.38, 3.04)	0.661	7	29.71	0.60 (0.26, 1.17)	0.181		
31-90	8	21.37	0.85 (0.38, 1.63)	0.664	2	7.04	0.78 (0.13, 2.57)	0.739	6	25.20	0.59 (0.23, 1.23)	0.208		
>90	3	7.24	1.02 (0.24, 2.95)	0.981	1	3.52	0.86 (0.05, 4.47)	0.888	4	11.55	0.92 (0.27, 2.34)	0.874		
Observation	period 2													
Unexposed	1,274	3331.54	1		2661	6393.54	1		11,799	27302.12	1			
Exposed	57	224.27	0.61 (0.46, 0.80)	< 0.001	99	204.97	1.32 (1.06, 1.62)	0.012	285	655.26	1.20 (1.05, 1.35)	0.005		

allergic rhinitis according to age group and observation period

Time since initiation of LTRA (days)

1-3	8	64.06	0.31 (0.14, 0.59)	0.001	18	59.39	0.79 (0.48, 1.23)	0.335	61	213.4	0.77 (0.59, 0.99)	0.047
4-7	10	34.56	0.72 (0.36, 1.27)	0.299	28	30.52	2.46 (1.65, 3.52)	< 0.001	111	105.38	2.85 (2.35, 3.43)	< 0.001
8-14	16	34.41	1.13 (0.66, 1.80)	0.625	26	29.36	2.40 (1.58, 3.47)	< 0.001	64	96.55	1.79 (1.38, 2.28)	< 0.001
15-30	10	38.32	0.62 (0.31, 1.09)	0.131	11	33.30	0.89 (0.46, 1.54)	0.707	25	105.01	0.64 (0.42, 0.93)	0.026
31-90	8	39.21	0.48 (0.21, 0.90)	0.039	12	33.90	0.97 (0.51, 1.66)	0.911	15	92.43	0.43 (0.25, 0.69)	0.001
>90	5	13.71	0.85 (0.29, 1.96)	0.733	4	18.50	0.58 (0.17, 1.45)	0.300	9	42.48	0.59 (0.27, 1.10)	0.126

Supplementary Table S3. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or

allergic rhinitis according to type of neuropsychiatric event and observation period.

	Psychotic disorder				Mood disorder				Anxiety disorder				Sleep-related disorder				Cognitive				Movement				Personality disorder			
Variable		Person e -year	IRR (95% CI)		No of events	Person -year	IRR (95% CI)	P- value		Person -year	IRR (95% CI)	P- value		Person -year	IRR (95% CI)			Person -year	IRR (95% CI)		No of events	Person -year	IRR (95% CI)	P- value	No of events	Person -year	IRR (95% CI)	P- value
Observation	ı per	iod 1																										
Unexposed	97	211.09	1		1,277	2752.8 3	1		3,057	6804.5 0	1		1916	4177.9 1	1		745	1811.5 8	1		106	216.11	1		78	170.05	1	
			0.57				1.01				0.97				0.63				0.71				1.43				0.6	
Exposed	2	7.76	(0.09,	0.440	34	80.23	(0.69,	0.944	71	186.71	(0.75,	0.808	30	109.15	(0.42,	0.018	31	98.11	(0.48,	0.078	4	8.73	(0.41,	0.521	2	6.83	(0.09,	0.498
			1.90)				1.44)				1.24)				0.91)				1.02)				3.78)				2.10)	
Time since i	initia	tion of	LTRA	(days)																								
							0.64				0.6				0.89				0.69				1.49					
1-3	0	1.87	NA	NA	6	21.59	(0.25,	0.285	13	53.48	(0.33,	0.071	12	31.56	(0.48,	0.701	8	26.37	(0.31,	0.307	1	1.86	(0.20,	0.697	0	1.76	NA	NA
							1.32)				1.00)				1.51)				1.31)				10.91)					
			1.81				1.78				1.55				0.42				1.03				2.57				2.05	
4-7	1	1.22	(0.25,	0.561	9	11.72	(0.85,	0.090	18	29.28	(0.94,	0.066	3	16.67	(0.10,	0.134	7	15.45	(0.44,	0.939	1	1.13	(0.35,	0.356	1	1.02	(0.27,	0.485
			13.28)				3.25)				2.41)				1.09)				2.02)				18.97)				15.31)	
							2.03				1.27				0.53				0.50				2.06				1.92	
8-14	0	1.34	NA	NA	11	12.57	(1.04,	0.022	15	30.23	(0.72,	0.364	4	17.25	(0.16,	0.211	4	18.29	(0.15,	0.165	1	1.40	(0.28,	0.479	1	1.11	(0.26,	0.527
							3.57)				2.05)				1.25)				1.17)				15.35)				14.37)	

			1.38				0.61				0.88				0.36				0.64				1.83					
15-30	1	1.64	(0.18,	0.752	4	15.40	(0.19,	0.332	11	32.07	(0.45,	0.666	3	19.56	(0.09,	0.076	6	20.59	(0.25,	0.291	1	1.72	(0.24,	0.559	0	1.45	NA	NA
			10.40)				1.45)				1.52)				0.94)				1.33)				13.88)					
							0.54				0.85				0.63				0.80									
31-90	0	1.57	NA	NA	3	13.23	(0.13,	0.298	9	27.08	(0.40,	0.635	5	17.42	(0.22,	0.313	5	13.61	(0.28,	0.634	0	1.71	NA	NA	0	1.19	NA	NA
							1.45)				1.57)				1.40)				1.79)									
							0.44				0.99				1.03				0.62									
. 00	0	0.12	NA	NA	1	5.71	(0.02,	0.436	5	14.58	(0.34,	0.984	3	6.69	(0.24,	0.959	1	3.80	(0.03,	0.635	0	0.92	NA	NA	0	0.30	NA	NA
>90							2.22)				2.33)				2.96)				3.07)									
Observation	ı peri	iod 2																										
T T 1	260	757 (1	1		4 001	8367.3	1			22319.	1		7.057	15805.	1		(21	1393.5				1440.2			170	221.17	1	
Unexposed	309	/5/.01	1		4,021	5	1		10,051	33	1		7,057	4	1		621	5	1		692	1	1		1/3	331.17	1	
			1.40				1.20				1.01				0.99				0.79				1.15				1.33	
Exposed	16	34.57	(0.79,	0.223	138	295.63	(1.00,	0.045	236	599.90	(0.88,	0.834	189	494.35	(0.85,	0.897	24	73.79	(0.51,	0.290	26	57.13	(0.74,	0.516	7	13.91	(0.54,	0.489
			2.33)				1.44)				1.16)				1.15)				1.19)				1.71)				2.79)	
Time since i	nitia	tion of	LTRA	(days)																								
			0.74				0.78				0.52				0.87				0.47				0.48				1.39	
0-3	2	7.23	(0.12,	0.666	24	75.08	(0.51,	0.234	40	194.68	(0.37,	< 0.001	50	147.85	(0.65,	0.317	4	21.18	(0.14,	0.130	3	15.10	(0.12,	0.204	2	3.47	(0.34,	0.650
			2.31)				1.13)				0.70)				1.13)				1.09)				1.25)				5.70)	
			0.61				2.01				2.40				1.92				1.13				2.50					
4-7	1	4.52	(0.03,	0.626	34	41.85	(1.40, -	< 0.001	89	94.39	(1.92,	< 0.001	59	79.25	(1.46,	< 0.001	5	10.92	(0.40,	0.790	8	7.72	(1.13,	0.011	0	2.11	NA	NA
			2.74)				2.78)				2.94)				2.46)				2.46)				4.74)					

			3.43			2.19	1.58				1.34		1.	.13		1.65				3.60		
8-14	6	5.1	(1.33, 0.004	38	43.47	(1.55, <0.001	53	85.20 (1.19, 0.00	40	77.23	(0.96, 0.070	5	10.81 (0).40, 0.792	5	7.32	(0.59, 0.270	3	2.06	(1.11,	0.032	
			7.21)			2.99)		2.06)			1.81)		2.	.46)			3.61)			11.6)		
			0.47			1.08		0.77			0.52		0).19			1.05			1.30		
15-30	1	6.34	(0.03, 0.450	22	51.71	(0.69, 0.708	29	95.46 (0.52, 0.16	. 17	83.59	(0.31, 0.007	1	12.85 (0).01, 0.097	4	9.22	(0.32, 0.923	1	1.92	(0.18,	0.797	
			2.11)			1.62)		1.09)			0.81)		0.	.84)			2.49)			9.50)		
			2.47			0.71		0.47			0.54		1.	.27			0.75			1.04		
31-90	5	6.97	(0.85, 0.059	15	54.72	(0.41, 0.200	16	87.13 (0.27, 0.00)	8 16	76.24	(0.31, 0.014	7	13.57 (0).53, 0.546	3	10.73	(0.18, 0.632	1	2.41	(0.14,	0.971	
			5.72)			1.15)		0.74)			0.85)		2.	.56)			2.03)			7.82)		
			0.92			0.49		0.57			0.55		1.	.16			1.30					
>90	1	4.42	(0.05, 0.935	5	28.79	(0.17, 0.123	9	43.06 (0.26, 0.10	7	30.20	(0.23, 0.130	2	4.47 (0).19, 0.839	3	7.04	(0.30, 0.681	0	1.94	NA	NA	
			4.78)			1.1)		1.07)			1.11)		3.	.98)			3.97)					

		Ast	hma	Allergic rhinitis only						
Variable	No of events	Person- year	IRR (95% CI)	P-value	No of events	Person- year	IRR (95% CI)	P-value		
Unexposed	12,950	30489.35	1		8,078	19057.54	1			
Exposed	409	1059.03	1.00 (0.90, 1.10)	0.938	162	396.95	1.19 (1.01, 1.39)	0.038		
Time since initia	ation of LTRA (da	ys)								
1-3	86	310.60	0.71 (0.57, 0.87)	0.002	29	134.10	0.75 (0.42, 0.87)	0.010		
4-7	118	161.45	1.87 (1.55, 2.24)	< 0.001	62	66.93	2.14 (2.06, 3.42)	< 0.001		
8-14	90	160.14	1.44 (1.16, 1.77)	0.001	43	61.86	1.63 (1.47, 2.70)	< 0.001		
15-30	48	182.12	0.67 (0.50, 0.88)	0.006	18	62.64	0.67 (0.50, 1.28)	0.426		
31-90	43	166.93	0.65 (0.47, 0.87)	0.006	8	52.21	0.60 (0.20, 0.83)	0.022		
>90	24	77.79	0.81 (0.52, 1.22)	0.347	2	19.20	0.76 (0.05, 0.92)	0.082		

Supplementary Table S4. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or

allergic rhinitis according to indication of leukotriene receptor antagonist

		Mo	ontelukast	Pranlukast						
Variable	No of events	Person-year	IRR (95% CI)	P-value	No of events	Person-year	IRR (95% CI)	P-value		
Unexposed	16,114	37889.88	1		2,730	6599.50	1			
Exposed	416	1077.87	1.07 (0.96, 1.18)	0.210	57	95.22	1.81 (1.36, 2.36)	<0.001		
Time since initi	ation of LT	'RA (days)								
1-3	83	313.00	0.72 (0.58, 0.89)	0.003	12	38.69	0.91 (0.51, 1.60)	0.735		
4-7	122	164.19	2.03 (1.68, 2.42)	< 0.001	22	16.83	3.92 (2.56, 6.02)	< 0.001		
8-14	91	162.92	1.54 (1.24, 1.88)	< 0.001	16	14.68	3.34 (2.02, 5.52)	< 0.001		
15-30	53	185.87	0.78 (0.59, 1.02)	0.077	5	12.93	1.18 (0.48, 2.86)	0.720		
31-90	45	171.67	0.72 (0.53, 0.96)	0.034	2	9.05	0.68 (0.17, 2.79)	0.592		
>90	22	80.23	0.79 (0.49, 1.20)	0.296	0	3.05	NA	NA		

Supplementary Table S5. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or

allergic rhinitis according to type of leukotriene receptor antagonist

Supplementary Table S6. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or

allergic rhinitis according to sex

			Male	Female							
Variable	No of events	Person-year	IRR (95% CI)	P-value	No of events	Person-year	IRR (95% CI)	P-value			
Unexposed	8,560	20806.96	1		12,468	28739.93	1				
Exposed	280	730.54	1.07 (0.94, 1.22)	0.266	291	725.44	1.04 (0.91, 1.17)	0.567			
Time since initi	ation of LT	TRA (days)									
1-3	61	197.31	0.86 (0.66, 1.10)	0.257	54	247.39	0.56 (0.42, 0.72)	< 0.001			
4-7	70	111.79	1.75 (1.37, 2.21)	< 0.001	110	116.59	2.41 (1.98, 2.90)	< 0.001			
8-14	71	116.31	1.69 (1.32, 2.13)	< 0.001	62	105.68	1.51 (1.16, 1.93)	0.001			
15-30	34	130.64	0.71 (0.50, 0.98)	0.051	32	114.12	0.72 (0.50, 1.01)	0.068			
31-90	27	122.05	0.60 (0.40, 0.87)	0.010	24	97.10	0.63 (0.41, 0.93)	0.029			
>90	17	52.43	0.95 (0.55, 1.54)	0.851	9	44.56	0.51 (0.24, 0.96)	0.057			

Supplementary Table S7. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with severe

	Total period					C	bs period 1		Obs period 2				
Variable	No of	Person-	IRR (95% CI)	P-value	No of	Person-	IRR (95% CI)		No of	Person-			
	events	year	IKK (95% CI)	F -value	events	year	IKK (95% CI)	P-value	events	year	IRR (95% CI)	P-value	
Unexposed	21028	49546.89	1		5,294	12519.69	1		15,734	37027.20	1		
Exposed	571	1455.98	1.05 (0.96, 1.15)	0.266	130	371.49	0.88 (0.73, 1.06)	0.185	441	1084.50	1.11 (1.00, 1.22)	0.047	
Time since in	itiation of	LTRA (days)										
1-3	6	21.77	0.63 (0.25, 1.3)	0.269	5	13.93	0.80 (0.28, 1.74)	0.616	1	7.85	0.30 (0.02, 1.36)	0.236	
4-7	10	15.41	1.48 (0.73, 2.63)	0.228	5	9.98	1.09 (0.39, 2.4)	0.843	5	5.43	2.19 (0.77, 4.83)	0.087	
8-14	10	19.54	1.18 (0.59, 2.11)	0.604	7	12.44	1.24 (0.52, 2.45)	0.584	3	7.10	1.04 (0.26, 2.76)	0.944	
15-30	8	26.98	0.69 (0.31, 1.31)	0.304	5	15.96	0.69 (0.24, 1.53)	0.424	3	11.03	0.68 (0.17, 1.80)	0.505	
31-90	9	31.49	0.66 (0.31, 1.23)	0.231	6	16.73	0.77 (0.30, 1.63)	0.535	3	14.77	0.52 (0.13, 1.40)	0.267	
>90	5	18.00	0.65 (0.22, 1.52)	0.377	2	7.50	0.60 (0.09, 2.07)	0.494	3	10.51	0.78 (0.18, 2.31)	0.697	

asthma according to type of observation period

Supplementary Table S8. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or allergic rhinitis, allowing for a 3-month interval between events


		Т	otal period			C	bs period 1	Obs period 2				
Variable	No of	Person-		. <u>.</u>	No of Person-		· · · · · · · · · · · · · · · · · · ·	No of Person	Person-			
	events	year	IRR (95% CI)	P-value	events year		IRR (95% CI)	P-value	events	year	IRR (95% CI)	P-value
Unexposed	24240	49546.89	1		6,079	12519.69	1		18,161	37027.20	1	
Exposed	680	1455.98	0.92 (0.85, 0.99)	0.038	148	371.49	0.81 (0.68, 0.96)	0.015	532	1084.50	1.02 (0.93, 1.12)	0.663
Time since ini	tiation of 2	LTRA (days)									
1-3	139	444.70	0.62 (0.53, 0.73)	< 0.001	32	107.86	0.60 (0.42, 0.84)	0.004	107	336.85	0.67 (0.55, 0.81)	< 0.001
4-7	193	228.38	1.68 (1.45, 1.93)	< 0.001	32	57.92	1.12 (0.77, 1.56)	0.540	161	170.46	1.99 (1.69, 2.32)	< 0.001
8-14	147	221.99	1.31 (1.11, 1.54)	0.001	31	61.66	1.03 (0.70, 1.44)	0.892	116	160.33	1.51 (1.25, 1.81)	< 0.001
15-30	81	244.77	0.64 (0.51, 0.80)	< 0.001	25	68.13	0.74 (0.48, 1.08)	0.144	56	176.64	0.65 (0.49, 0.83)	0.001
31-90	69	219.15	0.59 (0.46, 0.75)	< 0.001	18	53.61	0.66 (0.40, 1.03)	0.088	51	165.54	0.61 (0.46, 0.80)	0.001
>90	51	96.99	1.00 (0.73, 1.33)	0.99	10	22.30	0.99 (0.48, 1.04)	0.975	41	74.69	1.11 (0.79, 1.54)	0.528

Variable	No of	Person-										
	events	year	IRR (95% CI)	P-value	No of events	Person- year	IRR (95% CI)	P-value	No of events	Person- year	IRR (95% CI)	P-value
Unexposed	2,759	6393.79	1		3872	8101.20	1		17,609	35051.90	1	
Exposed	122	378.82	0.63 (0.52, 0.76)	< 0.001	138	251.11	1.13 (0.94, 1.36)	0.172	420	826.05	1.02 (0.92, 1.12)	0.768
Time since ini	itiation of	LTRA (day	ys)									
1-3	15	107.73	0.29 (0.17, 0.47)	< 0.001	32	71.96	0.90 (0.62, 1.26)	0.557	92	265.02	0.70 (0.57, 0.86)	0.001
4-7	25	58.84	0.88 (0.57, 1.27)	0.510	33	37.69	1.81 (1.26, 2.52)	0.001	135	131.86	2.05 (1.72, 2.42)	< 0.001
8-14	28	62.37	0.90 (0.61, 1.29)	0.601	32	36.83	1.81 (1.25, 2.53)	0.001	87	122.80	1.41 (1.13, 1.73)	0.002
15-30	22	68.37	0.62 (0.39, 0.93)	0.028	17	41.68	0.83 (0.49, 1.30)	0.441	42	134.72	0.61 (0.44, 0.82)	0.002
31-90	18	60.57	0.55 (0.33, 0.85)	0.013	16	40.94	0.76 (0.44, 1.22)	0.296	35	117.63	0.57 (0.40, 0.79)	0.001
>90	14	20.94	1.24 (0.67, 2.13)	0.460	8	22.01	0.78 (0.34, 1.56)	0.518	29	54.03	1.03 (0.68, 1.51)	0.871

Supplementary Table S9. Risk of neuropsychiatric events in relation to leukotriene receptor antagonist use in patients with asthma or allergic rhinitis according to age groups, allowing for a 3-month interval between events

Supplementary Figure S1. Histogram of time intervals from leukotriene receptor antagonist prescription date to neuropsychiatric

event



REFERENCE

1. Farrington, P., Whitaker, H., & Weldeselassie, Y.G. (2018). Self-Controlled Case Series Studies: A Modelling Guide with R (2nd ed.).

Chapman and Hall/CRC